{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:22:51Z","timestamp":1781169771218,"version":"3.54.1"},"reference-count":50,"publisher":"Rambam Health Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>Obesity is a complex, multifactorial disease that contributes to a broad range of cardiometabolic, reproductive, and psychological disorders. Representing a major global health challenge, obesity can be addressed by lifestyle modifications such as reduced calorie intake, physical activity, adequate sleep, and stress manage\u00acment to help achieve sustainable weight loss and improve metabolic health in the long term. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two naturally produced incretin hormones in the gastrointestinal tract. Incretin analogues were initially approved for type 2 diabetes mellitus but were later found to exhibit weight-reducing properties. Liraglutide, semaglutide, and tirzepatide are the three incretin analogues approved for obesity in non-diabetic patients. This narrative review presents detailed comparisons of the three approved incretin analogues for obesity, their cost-effectiveness, and trends in the clinical setting.<\/jats:p>","DOI":"10.5041\/rmmj.10565","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:17:48Z","timestamp":1769599068000},"page":"e0006","source":"Crossref","is-referenced-by-count":2,"title":["Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control"],"prefix":"10.5041","volume":"17","author":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Bonga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0292-1882","authenticated-orcid":false,"given":"Milan","family":"Padhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metab 2021;23 (Suppl 1):3-16.","DOI":"10.1111\/dom.14290"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"706978","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics","volume":"12","author":"Lin","year":"2021","unstructured":"2. Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (Lausanne) 2021; 12:706978.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2017.05.013","article-title":"Obesity and hypertension","volume":"122","author":"Seravalle","year":"2017","unstructured":"3. Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res 2017;122:1-7.","journal-title":"Pharmacol Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.fertnstert.2017.01.017","article-title":"Obesity and female infertility: potential mediators of obesity's impact","volume":"107","author":"DE","year":"2017","unstructured":"4. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. Fertil Steril 2017;107:840-7.","journal-title":"Fertil Steril"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/1878-0261.12772","article-title":"Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms","volume":"15","author":"Friedenreich","year":"2021","unstructured":"5. Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol 2021;15:790-800.","journal-title":"Mol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11154-023-09805-5","article-title":"Physical activity and exercise for weight loss and maintenance in people living with obesity","volume":"24","author":"Oppert","year":"2023","unstructured":"6. Oppert JM, Ciangura C, Bellicha A. Physical activity and exercise for weight loss and maintenance in people living with obesity. Rev Endocr Metab Disord 2023;24:937-49.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"KA","year":"2024","unstructured":"7. Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA 2024;332:571-84.","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","unstructured":"8. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne) 2024;15: 1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/MCG.0000000000001718","article-title":"Comparison of the efficacy and safety of the FDA-approved intragastric balloon systems in a clinical setting","volume":"57","author":"Swei","year":"2023","unstructured":"9. Swei E, Almuhaidb A, Sullivan S, et al. Comparison of the efficacy and safety of the FDA-approved intragastric balloon systems in a clinical setting. J Clin Gastroenterol 2023;57:578-85.","journal-title":"J Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/a-2292-2494","article-title":"American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity","volume":"56","author":"Jirapinyo","year":"2024","unstructured":"10. Jirapinyo P, Hadefi A, Thompson CC, et al. American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Endoscopy 2024;56:437-56.","journal-title":"Endoscopy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","unstructured":"11. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016;40:1310-19.","journal-title":"Int J Obes (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","unstructured":"12. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","unstructured":"13. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325:1403-13.","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","unstructured":"14. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-25.","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","unstructured":"15. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327:138-50.","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","unstructured":"16. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16.","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","unstructured":"17. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18.","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.18553\/jmcp.2025.31.5.441","article-title":"Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: a short-term cost-effectiveness analysis in the United States","volume":"31","author":"Liu","year":"2025","unstructured":"18. Liu L, Cui J, Neidecker MV, Nahata MC. Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: a short-term cost-effectiveness analysis in the United States. J Manag Care Spec Pharm 2025;31:441-50.","journal-title":"J Manag Care Spec Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","unstructured":"19. Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA 2023;330:2000-15.","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","article-title":"Liraglutide and glycaemic outcomes in the LEADER trial","volume":"9","author":"Zinman","year":"2018","unstructured":"20. Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, \u00d8rsted DD, Buse JB. Liraglutide and glycaemic outcomes in the LEADER trial. Diabetes Ther 2018;9:2383-92.","journal-title":"Diabetes Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","unstructured":"21. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","unstructured":"22. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","unstructured":"23. Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J 2024;267:1-11.","journal-title":"Am Heart J"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review. Int J Mol Sci 2024;25.","DOI":"10.3390\/ijms25084346"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","unstructured":"25. Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 2024; 47:1873-88.","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Somagutta MR, Jain M, Uday U, et al. Novel antidiabetic medications in polycystic ovary syndrome. Discoveries (Craiova) 2022;10:e145.","DOI":"10.15190\/d.2022.4"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. J Clin Med 2023;12.","DOI":"10.3390\/jcm12185915"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"520511","DOI":"10.3748\/wjg.v30.i48.5205","article-title":"GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"30","author":"Singh","year":"2024","unstructured":"28. Singh A, Sohal A, Batta A. GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024;30:520511.","journal-title":"World J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause TM. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am J Manag Care 2025;31:e228-e34.","DOI":"10.37765\/ajmc.2025.89778"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"13090","DOI":"10.1038\/s41598-023-40366-4","article-title":"Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome","volume":"13","author":"FPC","year":"2023","unstructured":"30. Freitas FPC, Rodrigues CEM. Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome. Sci Rep 2023;13:13090.","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14656566.2024.2437525","article-title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review","volume":"26","author":"El-Solh","year":"2025","unstructured":"31. El-Solh AA, Gould E, Aibangbee K, Jimerson T, Hartling R. Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review. Expert Opin Pharmacother 2025;26:51-62.","journal-title":"Expert Opin Pharmacother"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1007\/s11695-025-08210-y","article-title":"Interest in treatment with GLP-1 receptor agonists for the management of insufficient weight loss or weight regain after bariatric surgery","volume":"35","author":"Abdallah","year":"2025","unstructured":"32. Abdallah H, Klink WH, Derienne J, et al. Interest in treatment with GLP-1 receptor agonists for the management of insufficient weight loss or weight regain after bariatric surgery. Obes Surg 2025;35:4286-91.","journal-title":"Obes Surg"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"112910","DOI":"10.1016\/j.diabres.2025.112910","article-title":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial","volume":"229","author":"Sklepinski","year":"2025","unstructured":"33. Sklepinski SM, Deng Y, Swarna KS, et al. Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract 2025;229: 112910.","journal-title":"Diabetes Res Clin Pract"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","unstructured":"34. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427-37.","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","unstructured":"35. Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84.","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C(10))","volume":"11","author":"Twarog","year":"2019","unstructured":"36. Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ. Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C(10)). Pharmaceutics 2019;11:78.","journal-title":"Pharmaceutics"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","unstructured":"37. Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord 2022;23:979-94.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Tsipas S, Khan T, Loustalot F, Myftari K, Wozniak G. Spending on glucagon-like peptide-1 receptor agonists among US adults. JAMA Netw Open 2025;8: e252964.","DOI":"10.1001\/jamanetworkopen.2025.2964"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","unstructured":"39. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-81.","journal-title":"Gastroenterology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"107148","DOI":"10.4292\/wjgpt.v16.i3.107148","article-title":"Glucagon-like peptide-1 receptor agonists: evolution, gastrointestinal adverse effects, and future directions","volume":"16","author":"Ismail","year":"2025","unstructured":"40. Ismail A, Amer MS, Tawheed A. Glucagon-like peptide-1 receptor agonists: evolution, gastrointestinal adverse effects, and future directions. World J Gastrointest Pharmacol Ther 2025;16:107148.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","unstructured":"41. Ismaiel A, Scarlata GGM, Boitos I, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond) 2025;49:1946-57.","journal-title":"Int J Obes (Lond)"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Wen J, Nadora D, Truong A, et al. Next generation dual GLP-1\/GIP, GLP-1\/glucagon, and triple GLP-1\/GIP\/glucagon agonists: a literature review. Nutr Metab Cardiovasc Dis 2025:104213.","DOI":"10.1016\/j.numecd.2025.104213"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"102027","DOI":"10.1016\/j.molmet.2024.102027","article-title":"Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice","volume":"89","author":"Petersen","year":"2024","unstructured":"43. Petersen J, Merrild C, Lund J, Holm S, Clemmensen C. Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice. Mol Metab 2024;89:102027.","journal-title":"Mol Metab"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Novograd J, Mullally JA, Frishman WH. Tirzepatide for weight loss: can medical therapy \"outweigh\" bariatric surgery? Cardiol Rev 2023;31:278-83.","DOI":"10.1097\/CRD.0000000000000515"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1111\/dom.15796","article-title":"The role of incretin receptor agonists in the treatment of obesity","volume":"26","author":"Forst","year":"2024","unstructured":"45. Forst T, De Block C, Del Prato S, et al. The role of incretin receptor agonists in the treatment of obesity. Diabetes Obes Metab 2024;26:4178-96.","journal-title":"Diabetes Obes Metab"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","unstructured":"46. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-64.","journal-title":"Diabetes Obes Metab"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study","volume":"73","author":"Moll","year":"2024","unstructured":"47. Moll H, Frey E, Gerber P, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine 2024;73:102661.","journal-title":"EClinicalMedicine"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Floegel-Shetty A. Should pharmaceuticals be used as weight loss interventions for adolescents classified as obese by BMI? AMA J Ethics 2023;25:E478-95.","DOI":"10.1001\/amajethics.2023.478"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","unstructured":"49. Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 2023;389:514-26.","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","unstructured":"50. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023;402: 720-30.","journal-title":"Lancet"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/3338\/1\/PublishFiles\/4004Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:35:07Z","timestamp":1769600107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/69\/articles\/4004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,28]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10565","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}